Proportional Classifications of COPD Phenotypes
Overview
Authors
Affiliations
Background: Chronic obstructive pulmonary disease (COPD) encompasses a group of disorders characterised by the presence of incompletely reversible airflow obstruction with overlapping subsets of different phenotypes including chronic bronchitis, emphysema or asthma. The aim of this study was to determine the proportion of adult subjects aged >50 years within each phenotypic subgroup of COPD, defined as a post-bronchodilator ratio of forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) <0.7, in accordance with current international guidelines.
Methods: Adults aged >50 years derived from a random population-based survey undertook detailed questionnaires, pulmonary function tests and chest CT scans. The proportion of subjects in each of 16 distinct phenotypes was determined based on combinations of chronic bronchitis, emphysema and asthma, with and without incompletely reversible airflow obstruction defined by a post-bronchodilator FEV(1)/FVC ratio of 0.7.
Results: A total of 469 subjects completed the investigative modules, 96 of whom (20.5%) had COPD. Diagrams were constructed to demonstrate the relative proportions of the phenotypic subgroups in subjects with and without COPD. 18/96 subjects with COPD (19%) had the classical phenotypes of chronic bronchitis and/or emphysema but no asthma; asthma was the predominant COPD phenotype, being present in 53/96 (55%). When COPD was defined as a post-bronchodilator FEV(1)/FVC less than the lower limit of normal, there were one-third fewer subjects with COPD and a smaller proportion without a defined emphysema, chronic bronchitis or asthma phenotype.
Conclusion: This study provides proportional classifications of the phenotypic subgroups of COPD which can be used as the basis for further research into the pathogenesis and treatment of this heterogeneous disorder.
Is It Time Alpha-1 Antitrypsin Deficiency Had a Specific Patient Reported Outcome Measure? A Review.
De Soyza J, Chien H, Onasanya A, Turner A Patient Relat Outcome Meas. 2025; 16():23-35.
PMID: 39830373 PMC: 11742593. DOI: 10.2147/PROM.S490849.
Dal Negro R, Turco P, Povero M Int J Chron Obstruct Pulmon Dis. 2024; 19():2123-2133.
PMID: 39351081 PMC: 11439895. DOI: 10.2147/COPD.S467138.
Desjardins M, Jomphe V, Lagadec-Gaulin L, Cohen M, Abbott K J Speech Lang Hear Res. 2024; 67(8):2483-2498.
PMID: 38980884 PMC: 11305610. DOI: 10.1044/2024_JSLHR-23-00673.
Takahashi N, Nakashima R, Nasu A, Hayashi M, Fujikawa H, Kawakami T Antioxidants (Basel). 2024; 13(1).
PMID: 38247455 PMC: 10812479. DOI: 10.3390/antiox13010030.
Lee S, Lee H, Park H Eur J Med Res. 2022; 27(1):215.
PMID: 36307832 PMC: 9617312. DOI: 10.1186/s40001-022-00861-2.